de Castro G Jr et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2022;41(11):1986-91. Abstract

Doi T et al. DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study. ESMO 2022;Abstract 4530.

Garassino MC et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41(11):1992-8. Abstract

Garassino MC et al. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach. ASCO 2022;Abstract 9051.

Garon EB et al. EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC). ASCO 2022;Abstract TPS9146.

Gazzah A et al. Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events. ASCO 2023;Abstract e15003.

Isambert N et al. Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study). ELCC 2023;Abstract 13MO.

Johnson M et al. Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y). ESMO 2022;Abstract LBA59.

Leal T et al. Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. ASCO 2023;Abstract LBA9005.

Leal T et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): A randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023;24(9):1002-17. Abstract

Lisberg AE et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. ESMO 2023;Abstract LBA12.

Ricordel C et al. Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). ASCO 2022;Abstract 9039.

Rosner S et al. Antibody-drug conjugates for lung cancer: Payloads and progress. Am Soc Clin Oncol Educ Book 2023;43(43):e389968. Abstract

Yu H et al. Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFRTKI and platinum-based chemotherapy: HERTHENA-Lung01. WCLC 2023;Abstract OA05.03.